Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1151 • ACR Convergence 2021
Experiences and Finding Meaning Among Latin Americans Living with Lupus: Learning from Social Media Narratives by Patients and Their Social Network
Tirsa Colmenares-Roa¹, Alfonso Gastelum-Strozzi², Erica Crosley³, Yurilis Fuentes-Silva⁴, Cristina Reategui-Sokolova⁵, Claudia Elera-Fitzcarrald⁶, Soledad Ibañez⁷, Ernesto Cairoli⁸, Bernardo A. Pons-Estel⁹, Ingris Peláez-Ballestas¹ and Cristina Drenkard¹⁰, ¹Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico, Mexico, ²Instituto de Ciencias Aplicadas y Tecnología, Universidad Nacional Autónoma de México, Mexico, Mexico, ³John Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁷Sanatorio Güemes, Buenos Aires, Argentina, ⁸Autoimmune Diseases Unit, Centro Asistencial del Sindicato Médico del Uruguay (CASMU) and Hospital Evangélico, Montevideo, Uruguay, ⁹Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ¹⁰Emory University, Atlanta, GA
Background/Purpose: SLE disproportionately affects Latin Americans, and outcomes are worse amongst them compared to non-minority populations. Understanding patients' views of living with SLE is critical…
Abstract Number: 1266 • ACR Convergence 2021
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
Meghan Nelson¹, Lori Ponder², Sinclair Gibson³, D. Sofia Villacis- Nunez¹, Lai Hin Kimi Chan³, Lakshmi Moorthy⁴ and Sampath Prahalad⁵, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Children’s Healthcare of Atlanta, Atlanta, GA, ⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood systemic lupus erythematosus (cSLE) is a life-long disease with significant morbidity and mortality, and with associated significant impact on health-related quality of life…
Abstract Number: 1282 • ACR Convergence 2021
Classification of Disease Activity and Damage in Cutaneous Lupus
Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…
Abstract Number: 1298 • ACR Convergence 2021
Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
Martha Rodriguez¹, Kiana Rachele Johnson² and Kathleen O'Neil¹, ¹Riley Hospital for Children at Indiana University, Indianapolis, IN, ²East Tennessee state University, Johnson, TN
Background/Purpose: Pediatric Onset SLE is associated with higher disease activity and higher risk of damage. There is limited information on prepubertal patients with SLE and…
Abstract Number: 1460 • ACR Convergence 2021
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Mayce Haj-Ali¹, Kristina Deonaraine², Alexis Engel³, Yingzhi Qian¹, Amit Saxena⁴, Peter Izmirly², Jill Buyon⁴ and H. Michael Belmont⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
Abstract Number: 1493 • ACR Convergence 2021
Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg¹, Ruediger B. Mueller², Thomas Neumann³, Ian Pirker¹, Philipp Rein⁴, Camillo Ribi⁵, Andrea Rubbert-Roth⁶, Michael Kirschfink⁷, Jutta Schroeder-Braunstein⁷, Reinhard Voll⁸ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St.Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ³Kantonsspital St.Gallen, St.Gallen, Switzerland, ⁴Landeskrankenhaus Hohenems, Wolfurt, Austria, ⁵CHUV, Lausanne, Switzerland, ⁶Kantonspital St Gallen, St.Gallen, Switzerland, ⁷Universitätsklinikum Heidelberg, Heidelberg, Germany, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
Background/Purpose: Few reliable laboratory biomarkers exist to determine disease activity in SLE. The role of the soluble terminal complement complex, sC5b-9, in active SLE has…
Abstract Number: 1594 • ACR Convergence 2021
COVID-19 Pandemic-Related Changes in Health Routines and Self-Reported Physical Functioning Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim³ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic was disruptive to individual health routines. Changes in health routines may worsen disease management and reduce opportunities for physical activity, both…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 1751 • ACR Convergence 2021
Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Anca Askanase¹, Simrat Randhawa², Laura Lisk³ and Paola Mina-Osorio⁴, ¹Columbia University Medical Center, New York, NY, ²Aurinia Pharmaceuticals Inc., Seattle, WA, ³Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, ⁴Aurinia Pharmaceuticals Inc., New York, NY
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy.…
Abstract Number: 1769 • ACR Convergence 2021
BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects
Manoj Chiney¹, Ihab Girgis², Melanie Harrison¹, Xiaoping Zhang¹, Yun Shen³, Michelle Dawes¹, Lixian Dong², Diane Shevell³, Urvi Aras¹ and Bindu Murthy³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville
Background/Purpose: Toll like receptor (TLR) 7 and TLR8 are activated as part of the disease pathophysiology of systemic lupus erythematosus (SLE), including lupus nephritis (LN),…
Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Victoria Werth¹, Jodi Karnell², William Rees², Nanette Mittereder³, Li Yan², Yanping Wu³, Jorn Drappa², Gabor Illei² and John Ratchford², ¹University of Pennsylvania, Philadelphia, PA, ²Viela Bio, Gaithersburg, MD, ³Viela Bio, Gaithersburg
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
Abstract Number: 0002 • ACR Convergence 2020
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
Cristiano Moura¹, Marina Machado¹, Celline Almeida-Brasil¹, Jeffrey R Curtis², Kevin Winthrop³, Michal Abrahamowicz¹ and Sasha Bernatsky⁴, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Oregon Health & Science University, Portland, OR, ⁴The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…
Abstract Number: 0252 • ACR Convergence 2020
Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
Julie Birt¹, Jianmin Wu¹, Kirstin Griffing¹, Natalia Bello², Nicole Princic³, Isabelle Winer³, Carolyn Lew³ and Karen Costenbader⁴, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, ³IBM Watson Health, Cambridge, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is managed by variable combinations of five drug classes: antimalarials, biologics, corticosteroids, non-steroidal anti-inflammatory agents, and immunosuppressants. Opioids are commonly prescribed to SLE…
Abstract Number: 0269 • ACR Convergence 2020
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
Ehizogie Edigin¹, Precious Eseaton², Pius Ojemolon³ and Augustine Manadan⁴, ¹John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin Teaching Hospital, Benin, ³St. George's University, St. George's, Grenada, ⁴Cook County Hospital/Rush University Medical center, Chicago, IL
Background/Purpose: Libman-Sacks endocarditis characterized by thrombotic and/or non-infective sterile inflammatory vegetations are common in Systemic Lupus Erythematosus (SLE) and associated with increased morbidity. These vegetations…
Abstract Number: 0286 • ACR Convergence 2020
An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
Joseph Blake¹, Alexander Szalai², Jeffrey Edberg³ and James Mobley³, ¹UAB, Birmingham, ²University of Alabama at Birmingham, birmingham, AL, ³UAB, Birmingham, AL
Background/Purpose: SLE is a chronic and debilitating disease; in the USA with an estimated incidence of 3-10 per 100,000 people and currently affecting an estimated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].